Objective: Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable cardiovascular risk factor and emerging therapeutic target. Liraglutide, an analog of glucagon-like peptide-1, is indicated ...
The purpose of this study is to compare the efficacy and safety of liraglutide produced by CinnaGen company and Novo Nordisk liraglutide (Victoza®) in subjects with type II diabetes.
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to...
Novo Nordisk announced headline results from the second and final Phase IIIa trial with Victoza (liraglutide) as adjunct therapy to...
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in...
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide...
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
This is a 52 week, single center, open-labeled, randomized controlled trial.
A total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as contraindications to weight loss...
The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type...
Background: Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear.